Suppr超能文献

越南平定省恶性疟原虫对青蒿琥酯的体内敏感性。

In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam.

机构信息

Wellcome Trust Major Overseas Programme (MOP), Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh City, Vietnam.

出版信息

Malar J. 2012 Oct 26;11:355. doi: 10.1186/1475-2875-11-355.

Abstract

BACKGROUND

By 2009, there were worrying signs from western Cambodia that parasitological responses to artesunate-containing treatment regimens for uncomplicated Plasmodium falciparum malaria were slower than elsewhere which suggested the emergence of artemisinin resistance. Vietnam shares a long land border with Cambodia with a large number of migrants crossing it on a daily basis. Therefore, there is an urgent need to investigate whether there is any evidence of a change in the parasitological response to the artemisinin derivatives in Vietnam.

METHODS

From August 2010 to May 2011, a randomized controlled clinical trial in uncomplicated falciparum malaria was conducted to compare two doses of artesunate (AS) (2mg/kg/day versus 4 mg/kg/day for three days) followed by dihydroartemisinin-piperaquine (DHA-PPQ) and a control arm of DHA-PPQ. The goal was characterization of the current efficacy of artesunate in southern Vietnam. The primary endpoint of this study was the parasite clearance half-life; secondary endpoints included the parasite reduction ratios at 24 and 48 hours and the parasite clearance time.

RESULTS

166 patients were recruited into the study. The median parasite clearance half-lives were 3.54 (AS 2mg/kg), 2.72 (AS 4mg/kg), and 2.98 hours (DHA-PPQ) (p=0.19). The median parasite-reduction ratio at 24 hours was 48 in the AS 2mg/kg group compared with 212 and 113 in the other two groups, respectively (p=0.02). The proportions of patients with a parasite clearance time of >72 hours for AS 2mg/kg, AS 4mg/kg and DHA-PPQ were 27%, 27%, and 22%, respectively. Early treatment failure occurred in two (4%) and late clinical failure occurred in one (2%) of the 55 patients in the AS 2mg/kg group, as compared with none in the other two study arms. The PCR-corrected adequate clinical and parasitological response (APCR) rates in the three groups were 94%, 100%, and 100% (p=0.04).

CONCLUSIONS

This study demonstrated faster P. falciparum parasite clearance in southern Vietnam than in western Cambodia but slower clearance in comparison with historical data from Vietnam. Further studies to determine whether this represents the emergence of artemisinin resistance in this area are needed. Currently, the therapeutic response to DHA-PPQ remains satisfactory in southern Vietnam.

TRIAL REGISTRATION

NTC01165372.

摘要

背景

到 2009 年,柬埔寨西部出现了令人担忧的迹象,表明青蒿琥酯联合疗法治疗无并发症恶性疟原虫疟疾的寄生虫学反应比其他地区慢,这表明青蒿素耐药性已经出现。越南与柬埔寨有很长的陆地边界,每天都有大量移民过境。因此,迫切需要调查越南青蒿素衍生物的寄生虫学反应是否有任何变化的证据。

方法

2010 年 8 月至 2011 年 5 月,我们进行了一项随机对照临床试验,比较了青蒿琥酯(AS)两种剂量(2mg/kg/天与 3 天 4mg/kg/天)联合双氢青蒿素-哌喹(DHA-PPQ)和 DHA-PPQ 对照组,目的是描述越南南部青蒿琥酯的当前疗效。本研究的主要终点是寄生虫清除半衰期;次要终点包括 24 小时和 48 小时的寄生虫减少率和寄生虫清除时间。

结果

共有 166 名患者入组研究。AS 2mg/kg 组的中位寄生虫清除半衰期为 3.54 小时,AS 4mg/kg 组为 2.72 小时,DHA-PPQ 组为 2.98 小时(p=0.19)。AS 2mg/kg 组 24 小时的中位寄生虫减少率为 48,而其他两组分别为 212 和 113(p=0.02)。AS 2mg/kg、AS 4mg/kg 和 DHA-PPQ 的寄生虫清除时间>72 小时的患者比例分别为 27%、27%和 22%。AS 2mg/kg 组 55 例患者中,2 例(4%)发生早期治疗失败,1 例(2%)发生晚期临床失败,而其他两组均未发生。三组 PCR 校正的适当临床和寄生虫学反应(APCR)率分别为 94%、100%和 100%(p=0.04)。

结论

本研究表明,与柬埔寨西部相比,越南南部恶性疟原虫寄生虫清除速度更快,但与越南历史数据相比,清除速度较慢。需要进一步研究以确定这是否代表该地区青蒿素耐药性的出现。目前,DHA-PPQ 的治疗反应在越南南部仍然令人满意。

试验注册

NTC01165372。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0517/3504531/2e255fde9c1f/1475-2875-11-355-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验